Edgewise Therapeutics (EWTX) Stock: Buy, Sell, or Hold?
EWTX - Edgewise Therapeutics, Inc. Common Stock
$39.31
-0.68 (-1.70%)
▼
5d:
+5.7%
30d:
-4.49%
90d:
-5.5%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 23, 2026 at $39.31 · last confirmed Oct 23, 2026
Strength: 5.7/10
Get Alerted When EWTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EWTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: EWTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: EWTX is currently trading at $39.31, which is considered fair relative to its 30-day fair value range of $37.97 to $43.52.
Technical Outlook: Technically, EWTX is in a downtrend. Immediate support is located at $35.63, while resistance sits at $40.78.
Market Sentiment: EWTX scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $52.62 (+33.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EWTX is in a downtrend. Immediate support is located at $35.63, while resistance sits at $40.78.
Market Sentiment: EWTX scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $52.62 (+33.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$37.97 -
$43.52
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.8% below Wall St target ($52.62)
- BULLISH: Bottoming setup score 69/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$37.97 -
$43.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$35.63
Resistance Level
$40.78
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.16
Wall Street Target
$52.62
(+33.8%)
Share & Embed Analysis
Last updated: October 24, 2026 2:45 PM ET
Data refreshes hourly during market hours. Next update: 3:45 PM
Data refreshes hourly during market hours. Next update: 3:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EWTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 64 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |
